猪链球菌国内分离株精氨酸脱亚氨酶的克隆表达及其活性分析

根据GenBank上精氨酸脱亚氨酶(arginine deiminase,AD)序列AF546864,设计并合成一对引物,用PCR检测29株猪链球菌和7株马链球菌兽疫亚种的ad基因,发现29株猪链球菌均能检出此基因,而7株马链球菌兽疫亚种均未检出。扩增出的猪链球菌2型(SS2)强毒株HA9801的ad基因片段,定向克隆至pBAD/Myc-HisC严紧型质粒并转化TOP10。阳性重组菌经L-阿拉伯糖诱导,表达出分子量约47000Da的重组蛋白。经镍柱亲和层析,获得纯化的重组酶。活性分析显示,该酶具有巯基酶和金属酶的特征,其最适反应温度为37℃,最适pH值为6.5。Western blot分析显示,该酶能与SS2-HA9801全菌制备的兔抗血清发生特异性反应,表明其具有一定的免疫原性。检测该酶有助于进一步分析猪链球菌可能的毒力因子。     

家蚕精氨酸激酶原核表达纯化、结构与活性分析

精氨酸激酶(Arginine kinase,AK)是无脊椎动物体内能量代谢的关键酶,在生长发育、营养利用、免疫抗性、胁迫应答等生命活动过程中发挥着重要的调控作用。家蚕精氨酸激酶BmAK与能量平衡、抗NPV病毒过程相关,但目前关于其分子结构和酶学性质的研究不多。克隆了BmAK基因ORF序列,分析了其染色体定位、基因组结构、mRNA结构、二级结构和三级结构。进化分析表明AK在进化过程中高度保守。原核表达获得了可溶性的BmAK重组蛋白,通过Ni-NTA亲和层析纯化了BmAK。圆二色光谱分析显示BmAK包含α螺旋结构,其α螺旋结构在pH 5–10范围内相对稳定。酶活分析表明BmAK的最适温度为30℃,最适pH为7.5。25℃时BmAK的催化活性最大,在15–30℃范围内,BmAK的结构相对稳定,活性差别不大。BmAK的结构在pH 7.0左右相对稳定。这些研究为揭示BmAK的结构和功能提供了基础,有助于开发以AK为分子靶标的绿色安全环保的新型杀虫剂。     

链球菌噬菌体裂解酶在大肠杆菌中的表达、纯化及活性检测

噬菌体裂解酶是噬菌体产生的细胞壁水解酶,通过水解宿主菌细胞壁使子代噬菌体释放,在体外能高效且特异性地杀死细菌。本研究旨在克隆和表达链球菌噬菌体裂解酶PlyC,并测定其生物学活性。利用PCR方法扩增PlyC的2条肽链PlyCA和PlyCB,构建表达载体pET-32a(+)-PlyCA和pET-32a(+)-PlyCB,分别转化至大肠杆菌BL21(DE3)中,以0.7 mmol/L IPTG在30 oC诱导7 h实现了高效表达,SDS-PAGE分析表明PlyCA和PlyCB表达量均可达菌体总蛋白的30%以上。采用Ni2+-NTA亲和层析法纯化目的蛋白,其纯度大于95%。用透析复性方法得到目的产物重组链球菌噬菌体裂解酶PlyC,以浊度法和平板计数法检测其体外抗菌效果,扫描电子显微镜观察裂解酶作用前后细菌细胞形态变化。结果表明重组PlyC能特异性裂解化脓性链球菌(A组β-溶血性链球菌),以4μg/mL浓度作用于OD600为0.56的菌液60 min后杀菌率达99.6%,扫描电镜观察结果显示该酶作用于菌体后,链球菌细胞裂解,呈碎片状态。本研究为开发一种新型、高效的链球菌感染疾病治疗药物打下了基础。     

分选酶A(SrtA)的GST融合表达、纯化及活性测定

构建GST/金黄色葡萄球菌分选酶A (SrtA)的原核表达载体,在大肠杆菌中表达、纯化分选酶,并利用展示在酵母表面的底物检测分选酶的活性.以pMD20-SrtA为模板,PCR扩增得到SrlA△N59基因,经BamH I和Xho I双酶切,连接到原核表达栽体pGEX-4T-1中,构建重组表达栽体pGEX-SrtA△N59,转化大肠杆菌BL21( DE3),IPTG诱导表达,GST亲和层析分离纯化得到SrtA△N59,与展示在酵母表面的底物序列QALPETGEE-linker-EGFP作用,产生游离的EGFP,通过酶标仪检测EGFP荧光强度确定分选酶的活性.结果显示,重组表达栽体pGEX-SrtA△N59经IPTG诱导,表达出相对分子质量约为42 kD的融合蛋白,SDS-PAGE分析,该融合蛋白是以可溶形式表达.分离纯化得到的分选酶与底物作用,其荧光强度由568.66±12.14增加至921.43±13.02.以上结果表明,成功构建了重组表达裁体pGEX-SrtA△N59,并在大肠杆菌中获得了可溶表达的有活性的分选酶.     

蚯蚓纤溶酶基因P239的原核表达、纯化及活性测定

通过RT-PCR方法从蚯蚓(Lumbricus bimastus)中获得蚯蚓纤溶酶基因,命名为P-239,含有 852 个核苷酸,成熟肽编码 239 个氨基酸,通过Genbank 序列同源性比较,与已知的蚯蚓纤溶酶有一定的同源性,为首次获得的新基因.随后构建了pBV-220/P-239重组质粒,在大肠杆菌DH5α中进行原核表达,再经亲和层析柱纯化复性,其产物经活性测定,确定不仅具有激酶作用,而且具有直接溶栓活性.     

肽酰精氨酸的翻译后修饰

肽酰精氨酸残基甲基化作用是细胞质与细胞核内蛋白质翻译后修饰的普遍方式。精氨酸残基甲基化蛋白质与许多细胞生物学过程有关,包括转录调节、RNA代谢和DNA损伤修复等。生物体内精氨酸N-甲基转移酶类、肽酰精氨酸脱亚氨酶类与JMJD6等催化肽酰精氨酸残基进行甲基化、瓜氨酸化和去甲基化的动态修饰。这种动态修饰对细胞生物学功能有重要调节作用。     

一个新的人乙酰化酶MAK3的克隆、表达和纯化

在对乙酰GNAT家族进行研究分析的过程中,找到一个人GNAT家族的新成员MAK3。MAK3含有一个保守的乙酰化酶结构域,并且不同物种中的MAK3的蛋白质序列高度保守。通过半定量和定量RT—PCR检测了在不同组织中MAK3的mRNA水平。并且把MAK3分别克隆到了真核和原核表达质粒中,通过免疫印迹技术证实了MAK3的表达。还进一步用亲和层析的方法成功纯化了细菌中表达的MAK3,并对纯化后的MAK3的酶活性进行了测定。     

丝氨酸蛋白酶抑制剂Ea的表达纯化与活性分析

Ea是一种植物来源的丝氨酸蛋白酶抑制剂,分子量为18kD。利用其与丝氨酸蛋白酶家族成员的结合特性,可用于丝氨酸蛋白酶的结构与功能研究,也可作为亲和层析的配体而用于丝氨酸蛋白酶的纯化。将Ea基因插入大肠杆菌表达载体pET11a,在BL21(DE3)菌中以包涵体形式表达出重组蛋白质,表达量可占菌体蛋白质总量的30%。将包涵体变性、复性,得到具有天然抑制活性的rEa。经两步纯化所得rEa的纯度达到967%以上。活性分析表明,rEa对胰蛋白酶和人组织型纤溶酶原激活剂均有抑制作用。制备成rEaSepharose亲和柱可有效结合胰蛋白酶。     

重组人RGD-sTRAIL的表达、纯化及抗肿瘤活性研究

利用PCR技术构建RGD短肽与人肿瘤坏死因子凋亡配体(胞外区114-281)的融合基因,将该DNA片段克隆到原核表达载体pET-11a中。重组质粒转化大肠杆菌BL21(DE3),IPTG诱导后可表达相对分子质量约为20000的目的蛋白,占菌体蛋白的20％左右,且大多数重组蛋白以不溶的包涵体形式存在。Western印迹表明目的蛋白具有人sTRAIL的抗原性。表达产物经变性、复性、离子交换层析和分子筛等步骤,可以得到纯度大干95％的RGD-sTRAIL重组蛋白。肿瘤细胞体外实验发现,纯化后的RGD-sTRAIL重组蛋白能明显抑制人肺癌细胞A549生长,并呈剂量依赖性。研究结果表明,通过复性,包涵体中的RGD-sTRAIL蛋白得到正确的折叠,并在体外具有杀伤肿瘤细胞的活性,从而为进一步研究体内靶向性杀伤肿瘤细胞奠定了基础。     

尖吻蝮蛇毒中精氨酸脂酶的分离纯化与性质研究

目的：从尖吻蝮蛇蛇毒中纯化出精氨酸脂酶并进行性质研究。方法：利用亲和层析、DEAE—Sepharose FF、Superdex 75柱对尖吻蝮蛇毒进行分离纯化。结果：分离纯化出的2个精氨酸脂酶活性组份分子量分别为36000、30000,它们的HPLC纯度也都达到97％以上。结论：为其临床应用打下了基础。     

利用定点突变法研究精氨酸脱亚胺酶活性的影响机制

精氨酸脱亚胺酶(ADI)是一种针对精氨酸缺陷型癌症(如:肝癌、黑素瘤)的新药,目前处于临床三期试验。文中通过定点突变技术分析了精氨酸脱亚胺酶的特定氨基酸位点对酶活力的影响机制。针对已报道的关键氨基酸残基A128、H404、I410,采用QuikChange法进行定点突变,获得ADI突变株M1(A128T)、M2(H404R)、M3(I410L)和M4(A128T/H404R)。将突变株在大肠杆菌BL21(DE3)中进行重组表达,并对纯化获得的突变蛋白进行酶学性质研究。结果表明,突变位点A128T和H404R对ADI最适pH的提高,生理中性(pH 7.4)条件下的酶活力和稳定性的提高,以及Km值的降低均具有显著的作用。研究结果为阐明ADI的酶活力影响机制和蛋白质的理性改造提供了一定的依据。     

精氨酸脱亚胺酶在大肠杆菌中的分泌型表达

将变形假单胞菌的精氨酸脱亚胺酶(ADI)编码基因arc A克隆至具有阿拉伯糖启动子的分泌型表达载体pBAD/gⅢB中,经鉴定得到重组质粒pBAD-ADI。将重组质粒转化大肠杆菌TOP10F'后进行诱导表达,分别考察了不同诱导物L-arabinose浓度、诱导温度、诱导时间对重组蛋白表达的影响,最适诱导条件为L-arabinose浓度0.002%(w/v),25℃下诱导5 h,全细胞的酶活为68 mU/mL(指单位发酵液体积,下同)。采用Osmotic Shock法使ADI从胞周质释放出来,经检测分泌到胞周质的重组蛋白活性为53 mU/mL,细胞内的酶活为34 mU/mL。SDS-PAGE分析显示,重组蛋白大小约为46 kD。     

Purification,immobilization, and biochemical characterization of l‐arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: Anticancer activity in vitro

l ‐Arginine deiminase (ADI) has a powerful anticancer activity against various tumors, via arginine depletion, arresting the cell cycle at G₁ phase. However, the current clinically tried bacterial ADI displayed a higher antigenicity and lower thermal stability. Thus, our objective was to purify and characterize this enzyme from thermophilic fungi, to explore its catalytic and antigenic properties for therapeutic uses. ADI was purified from thermophilic Aspergillus fumigatus KJ434941 to its electrophoretic homogeneity by 5.1‐fold, with molecular subunit 50 kDa. The purified ADI was PEGylated and covalently immobilized on dextran to explore its catalytic properties. The specific activity of free ADI, PEG‐ADI, and Dex‐ADI was 26.7, 21.5, and 18.0 U/mg, respectively. At 50°C, PEG‐ADI displays twofold resistance to thermal denaturation (t_1/2 13.9 h), than free ADI (t_1/2 6.9 h), while at 70°C, the thermal stability of PEG‐ADI was increased by 1.7‐fold, with similar stability to Dex‐ADI with the free one. Kinetically, free ADI had the higher catalytic affinity to arginine, followed by PEG‐ADI and Dex‐ADI. Upon proteolysis for 30 min, the residual activity of native ADI, PEG‐ADI, and Dex‐AD was 8.0, 32.0, and 20.0% for proteinase K and 10.0, 52.0, and 90.0% for acid protease, respectively. The anticancer activity of the ADIs was assessed against HCT, HEP‐G2, and MCF7, in vitro. The free and PEG‐ADI exhibits a similar cytotoxic efficacy for the tested cells, lower than Dex‐ADI. The free ADI had IC₅₀ value 22.0, 16.6, and 13.9 U/mL, while Dex‐ADI had 3.98, 5.18, and 4.43 U/mL for HCT, MCF7, and HEPG‐2, respectively. The in vitro anticancer activity of ADI against HCT, MCF7, and HEPG‐2 was increased by five‐, three‐, and threefold upon covalent modification by dextran. The biochemical and hematological parameters of the experimented animals were not affected by ADIs dosing, with no signs of anti‐ADI immunoglobulins in vivo. The in vivo half‐life time of free ADI, PEG‐ADI, and Dex‐ADI was 29.7, 91.1, 59.6 h, respectively. The present findings explored a novel thermostable, less antigenic ADI from thermophilic A. fumigatus, with further molecular and crystallographic analyses, this enzyme will be a powerful candidate for clinical trials. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 31:396–405, 2015     

精氨酸脱亚胺酶发酵过程特性研究

精氨酸脱亚胺酶有较好的体内体外肿瘤生长抑制作用。通过对粪肠球菌（Enterococcus faecalis）NJ402菌株产精氨酸脱亚胺酶的发酵特性的研究,建立起代谢物的过程变化与精氨酸脱亚胺酶产生机理的内在联系。NJ402菌株生长过程中碳源物质代谢产生乳酸导致发酵体系pH的下降,而培养基中L-精氨酸的脱亚胺作用有利于发酵体系pH的稳定和菌体生长。进一步的研究表明,低pH生长环境有利于NJ402菌株产精氨酸脱亚胺酶,且精氨酸脱亚胺酶的产生与能量代谢无关。NJ402菌株产精氨酸脱亚胺酶受底物L-精氨酸的诱导,但该诱导作用受菌体生长体系pH的调控,即精氨酸脱亚胺酶的产生是低pH生长环境与L－精氨酸共同作用的结果。     

Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation

Protein citrullination is just one of more than 200 known PTMs. This modification, catalyzed by the protein arginine deiminases (PADs 1–4 and PAD6 in humans), converts the positively charged guanidinium group of an arginine residue into a neutral ureido-group. Given the strong links between dysregulated PAD activity and human disease, we initiated a program to develop PAD inhibitors as potential therapeutics for these and other diseases in which the PADs are thought to play a role. Streptonigrin which possesses both anti-tumor and anti-bacterial activity was later identified as a highly potent PAD4 inhibitor. In an effort to understand why streptonigrin is such a potent and selective PAD4 inhibitor, we explored its structure–activity relationships by examining the inhibitory effects of several analogues that mimic the A, B, C, and/or D rings of streptonigrin. We report the identification of the 7-amino-quinoline-5,8-dione core of streptonigrin as a highly potent pharmacophore that acts as a pan-PAD inhibitor.     

Insights into the structure and inhibition of Giardia intestinalis arginine deiminase: homology modeling,docking, and molecular dynamics studies

Giardia intestinalis arginine deiminase (GiADI) is an important metabolic enzyme involved in the energy production and defense of this protozoan parasite. The lack of this enzyme in the human host makes GiADI an attractive target for drug design against G. intestinalis. One approach in the design of inhibitors of GiADI could be computer-assisted studies of its crystal structure, such as docking; however, the required crystallographic structure of the enzyme still remains unresolved. Because of its relevance, in this work, we present a three-dimensional structure of GiADI obtained from its amino acid sequence using the homology modeling approximation. Furthermore, we present an approximation of the most stable dimeric structure of GiADI identified through molecular dynamics simulation studies. An in silico analysis of druggability using the structure of GiADI was carried out in order to know if it is a good target for design and optimization of selective inhibitors. Potential GiADI inhibitors were identified by docking of a set of 3196 commercial and 19 in-house benzimidazole derivatives, and molecular dynamics simulation studies were used to evaluate the stability of the ligand–enzyme complexes.     

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells

Background  

Sensitivity of cancer cells to recombinant arginine deiminase (rADI) depends on expression of argininosuccinate synthetase (AS), a rate-limiting enzyme in synthesis of arginine from citrulline. To understand the efficiency of RNA interfering of AS in sensitizing the resistant cancer cells to rADI, the down regulation of AS transiently and permanently were performed in vitro, respectively.     

Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency

Arginine deiminase (ADI) is a therapeutic protein for cancer therapy of arginine-auxotrophic tumors. However, its application as anticancer drug is hampered by its poor stability under physiological conditions in the bloodstream. Commonly, random PEGylation is being used for increasing the stability of ADI and in turn the improved half-life. However, the traditional random PEGylation usually leads to poor PEGylation efficiency due to the limited number of Lys on the protein surface. To boost the PEGylation efficiency and enhance the stability of ADI further, surface engineering of PpADI (an ADI from Pseudomonas plecoglossicida) to increase the suitable PEGylation sites was carried out. A new in silico approach for increasing the PEGylation sites was developed. The validation of this approach was performed on previously identified PpADI variant M31 to increase potential PEGylation sites. Four Arg residues on the surface of PpADI M31 were selected through three criteria and subsequently substituted to Lys, aiming for providing primary amines for PEGylation. Two out of the four substitutions (R299K and R382K) enhanced the stability of PEGylated PpADI in human serum. The average numbers of PEGylation sites were increased from ~12 (tetrameric PpADI M31, starting point) to ~20 (tetrameric PpADI M36, final variant). Importantly, the PEGylated PpADI M36 after PEGylation exhibited significantly improved T_m values (M31: 40°C; M36: 40°C; polyethylene glycol [PEG]-M31: 54°C; PEG-M36: 64°C) and half-life in human serum (M31: 1.9 days; M36: 2.0 days; PEG-M31: 3.2 days; PEG-M36: 4.8 days). These proved that surface engineering is an effective approach to increase the PEGylation efficiency which therefore enhances the stability of therapeutic enzymes. Furthermore, the PEGylated PpADI M36 represents a highly attractive candidate for the treatment of arginine-auxotrophic tumors.